TEL AVIV, ISRAEL — A groundbreaking discovery by researchers at Tel Aviv University has offered new hope for the estimated 250,000 to 500,000 people worldwide who sustain spinal cord injuries each year, with a new stem-cell therapy successfully restoring movement in laboratory models and showing promise for eventual human application .
The research team, led by Professor Tal Dvir from the university’s Department of Biotechnology and the Sagol Center for Regenerative Medicine, developed a novel approach that uses stem cells to repair damaged spinal cord tissue. The therapy involves the transplantation of engineered neural cells derived from human stem cells into the site of injury, where they integrate with existing tissue and help restore neural pathways.
In experiments conducted on animal models with spinal cord injuries, the treated subjects demonstrated significant recovery of motor function, including the ability to walk, within a relatively short period. The study, published in a leading peer-reviewed journal, marks a significant advancement over previous attempts to use stem cells for spinal cord repair, which had often failed to achieve meaningful functional recovery.
“The results are extremely promising,” said Professor Dvir in a press release. “We have shown that it is possible to regenerate damaged spinal cord tissue and restore movement, a feat that has eluded the medical community for decades. This could change the lives of millions of people living with paralysis.”
The new approach overcomes several key challenges that have plagued previous stem-cell therapies for spinal cord injuries. One of the main obstacles has been the hostile environment at the injury site, which is characterised by inflammation and the formation of scar tissue that inhibits nerve regeneration. The Tel Aviv University team developed a technique to deliver the stem cells within a supportive hydrogel that protects them from the hostile environment and promotes their integration into the surrounding tissue.
The research is still at the preclinical stage, and human trials are expected to begin within the next few years, pending regulatory approvals. However, the breakthrough has been hailed by scientists around the world as a major step forward in the field of regenerative medicine, and a source of hope for the millions of people living with spinal cord injuries.
“Our goal is to develop a safe and effective treatment that can be widely accessible,” Dvir said. “This is still a long journey, but this study gives us a solid foundation to move forward.”
The spinal cord injury community has also responded with cautious optimism. Advocacy groups have welcomed the breakthrough and called for accelerated funding for clinical trials and increased support for research into spinal cord injury treatments.
The World Health Organisation estimates that 250,000 to 500,000 people suffer from spinal cord injuries each year, with the majority of them being young adults. Current treatment options are limited to rehabilitation and management of symptoms, with no cure available. The Tel Aviv University breakthrough represents a significant advancement, offering hope for recovery and a better quality of life for millions. As the research moves toward human trials, the global medical community watches with anticipation.
